NMD Pharma Raises €35M Financing
- NMD Pharma, an Aarhus, Denmark-based clinical stage biotech company, raised €35M in funding
- The round was led by Jeito Capital with participation from INKEF Capital, Novo Holdings, Roche Venture Fund and Lundbeck Foundation
- Jeito Capital has joined the NMDPharma Board with Sabine Dandiguian, Managing Partner, as a Non-Executive Director
- NMDPharma is a biotech company advancing novel first-in-class therapies for severe neuromuscular disorders
- NMD has built a muscle electrophysiology platform leveraging the in-depth know-how of muscle physiology and muscular disorders, small molecule modulators
